Menopause
What human research has studied for hot flashes and other menopausal symptoms, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.
How strong the evidence is
Where menopause sits on the supplement body map; colored by its strongest grade here.
Findings by ingredient
| Ingredient | Grade | What was studied and found |
|---|---|---|
| Fennel | B | Menopausal symptoms. Two placebo-controlled RCTs (145 women) favored fennel for menopausal symptoms; other trials showed no benefit for sexual function, quality of life or psychological health, and risk of bias was concerning. sources |
| Red clover | B | Hot flashes in peri- and postmenopausal women. A 2026 meta-analysis of nine placebo-controlled RCTs (37.1–160 mg/day isoflavones, 12 weeks to 12 months) found a small-to-moderate reduction in hot-flash frequency; most trials had low risk of bias. sources |
| Red clover | B | Daily number of hot flashes. A 2021 meta-analysis of eight trials (ten comparisons) found 1.73 fewer hot flashes per day than placebo (95% CI -3.28 to -0.18); the authors call for further well-designed studies. sources |
| Royal jelly | B | Postmenopausal symptoms. A 2026 systematic review included 6 studies (471 postmenopausal women); pooling 2 studies (312 participants) showed improved symptoms versus placebo (SMD 0.73), rated moderate-quality evidence. sources |
| Soy isoflavones | B | Hot flashes in peri- and postmenopausal women. A 2012 meta-analysis of double-blind RCTs found soy isoflavones (median 54 mg/day, 6 weeks to 12 months) reduced hot-flash frequency by 20.6% and severity by 26.2% versus placebo, with high heterogeneity. sources |
| 5-HTP (5-hydroxytryptophan) | C | Menopausal hot flashes. A small double-blind trial in 24 postmenopausal women found no significant effect of 150 mg/day 5-HTP on objectively recorded hot-flash frequency; the author called it preliminary. sources |
| Bee pollen | C | Menopausal symptoms in breast cancer patients on antihormonal therapy. In a randomized crossover trial (46 patients recruited), 70.9% reported improvement with pollen-honey and 68.3% with honey alone; the difference was not significant. sources |
| Black cohosh | C | Menopausal symptoms (Cochrane review). A 2012 Cochrane review of 16 randomized trials (2,027 women) found insufficient evidence to support or oppose black cohosh for menopausal symptoms. sources |
| Black cohosh | C | Overall menopause symptoms (2023 review). A 2023 review of 22 studies, including combination products, found potential benefit for overall menopause symptoms and hot flashes but not for anxiety or depressive symptoms; results conflict with other reviews. sources |
| Black cohosh | C | Hot flashes from breast cancer treatment. NCCIH states it is uncertain whether black cohosh reduces hot flashes caused by breast cancer treatment. sources |
| Chasteberry (vitex) | C | Menopausal symptoms. In combination with St. John's wort, chasteberry was ineffective for menopausal symptoms. sources |
| Dong quai | C | Hot flashes and other menopausal symptoms (dong quai alone). A single 24-week double-blind trial in 71 postmenopausal women found no difference from placebo in hot flashes, Kupperman index, endometrial thickness or vaginal cell maturation. sources |
| Dong quai | C | Menopausal symptoms (all studies, including formulas). MSK describes findings on dong quai for menopausal symptoms as inconclusive and notes it was ineffective against hot flashes in men. sources |
| Hops | C | Menopausal symptoms in postmenopausal women. A few studies suggest hops extracts may alleviate menopausal symptoms. sources |
| Lavender | C | Menopause-related sexual dysfunction. One preliminary study of 72 postmenopausal women aged 50–65 found an oral lavender oil product might offer some relief; more reliable evidence is needed. sources |
| Maca | C | Menopausal symptoms. A 2011 systematic review of four randomized trials in peri- and postmenopausal women found favorable effects on symptom scores but rated the evidence limited because of few, small and lower-quality trials. sources |
| Resveratrol | C | Menopausal symptoms and well-being. In one long-term trial in postmenopausal women, resveratrol improved chronic pain, somatic menopausal symptoms, circulatory function and well-being. sources |
| Sage | C | Menopausal hot flashes. NCCIH: a few small studies suggest common sage may reduce how often hot flashes occur. sources |
| Sage | C | Hot flashes (pooled trials). A meta-analysis of 4 trials (310 women) reported a pooled effect on hot-flash frequency of ES −1.12 (95% CI −2.37 to 0.14), which was not statistically significant, and no significant effect on severity. sources |
| Schisandra | C | Menopausal symptoms. In a placebo-controlled trial (6 weeks of treatment, 12 weeks of follow-up; 36 women completed), Kupperman Index scores were lower with a Schisandra chinensis extract. sources |
| Sea buckthorn | C | Vaginal atrophy after menopause. In an RCT of 116 postmenopausal women, 3 g/day oil for 3 months improved vaginal epithelial integrity versus placebo (OR 3.1); the vaginal health index showed only a trend. sources |
| Shatavari | C | Menopausal symptoms. An 8-week, three-arm trial (135 women aged 45 to 65) found the shatavari-plus-ashwagandha combination improved menopause rating scores more than shatavari alone or placebo; it is a single trial from one research group. sources |
| Valerian | C | Menopause symptoms. Three small studies suggest valerian might help, but NCCIH states the evidence is not enough to know. sources |
| Black cohosh | X | Hot flashes and night sweats in large trials. A 12-month RCT (351 women) found no difference from placebo at 3, 6 or 12 months; a 2016 meta-analysis (4 studies, 511 women) found no significant reduction in vasomotor symptoms. sources |
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.